Mesoblast (MESO) Cash & Equivalents Growth (3y) (2018 - 2025)

Mesoblast (MESO) Cash & Equivalents Growth (3y) (2018 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -8.88%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Mesoblast 19.81 Bn 19.68 Bn - 24.34%

Historic Data

Download Data
DateValue
Dec 31, 2025 24.34%
Jun 30, 2025 38.78%
Dec 31, 2024 -26.26%
Jun 30, 2024 -22.81%
Dec 31, 2023 0.01%
Jun 30, 2023 -18.00%
Mar 31, 2023 -6.70%
Dec 31, 2022 -5.98%
Sep 30, 2022 35.28%
Jun 30, 2022 6.23%
Mar 31, 2022 2.93%
Dec 31, 2021 7.19%
Sep 30, 2021 28.12%
Jun 30, 2021 53.61%
Mar 31, 2021 38.52%
Dec 31, 2020 17.83%
Sep 30, 2020 19.76%
Jun 30, 2020 41.38%
Mar 31, 2020 -4.57%
Dec 31, 2019 33.88%